May 5 | 2021
Sista dag för handel med teckningsoptionerna av serie TO1 i 2cureX AB är idag, den 5 maj 2021
Read more
April 24 | 2021
Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021.
Read more
April 24 | 2021
Korrektion till ”Kallelse till årsstämma i 2cureX AB” utfärdad den 23 april 2021.
Read more
April 23 | 2021
Notice to attend the Annual General Meeting of 2cureX AB
Read more
April 23 | 2021
Kallelse till årsstämma i 2cureX AB
Read more
April 23 | 2021
Teckningskursen för utnyttjande av teckningsoptioner av serie TO1 i 2cureX AB har fastställts till 13,22 SEK och teckningsperioden inleds den 26 april 2021
Read more
April 23 | 2021
The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021
Read more
March 1 | 2021
2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.
Read more
February 25 | 2021
2cureX publishes year-end report for 2020.
Read more
February 25 | 2021
2cureX offentliggör bokslutskommuniké för räkenskapsåret 2020.
Read more
February 4 | 2021
IndiTreat® selected to prestigious multinational ovarian cancer project.
Read more
January 28 | 2021
2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO.
Read more
January 5 | 2021
2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO
Read more
November 26 | 2020
2cureX offentliggör delårsrapport för det tredje kvartalet 2020.
Read more
November 26 | 2020
2cureX publishes interim report for the third quarter of 2020.
Read more
November 5 | 2020
Announcement from 2cureX extra general meeting
Read more
November 5 | 2020
Kommuniké från extra bolagsstämma i 2cureX
Read more
October 14 | 2020
Kallelse till extra bolagsstämma i 2cureX AB
Read more